Obseva SA (OBSV) Receives $29.43 Average Price Target from Analysts
Obseva SA (NASDAQ:OBSV) has been assigned an average rating of “Buy” from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $29.43.
A number of equities research analysts have commented on the company. Zacks Investment Research upgraded Obseva from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a report on Thursday, October 18th. Wedbush assumed coverage on Obseva in a report on Monday, August 6th. They set an “outperform” rating and a $34.00 target price on the stock. HC Wainwright set a $44.00 target price on Obseva and gave the company a “buy” rating in a report on Wednesday, August 8th. Leerink Swann assumed coverage on Obseva in a report on Wednesday, August 15th. They set an “outperform” rating and a $25.00 target price on the stock. Finally, TheStreet upgraded Obseva from a “d+” rating to a “c-” rating in a report on Thursday, October 11th.
Several institutional investors have recently modified their holdings of the business. VHCP Management III LLC purchased a new position in shares of Obseva during the 3rd quarter worth $20,911,000. Renaissance Technologies LLC lifted its stake in shares of Obseva by 191.8% during the 3rd quarter. Renaissance Technologies LLC now owns 100,100 shares of the company’s stock worth $1,805,000 after purchasing an additional 65,800 shares during the period. Citadel Advisors LLC purchased a new position in shares of Obseva during the 3rd quarter worth $728,000. Vivo Capital LLC lifted its stake in shares of Obseva by 1.3% during the 3rd quarter. Vivo Capital LLC now owns 937,147 shares of the company’s stock worth $16,897,000 after purchasing an additional 12,147 shares during the period. Finally, GSA Capital Partners LLP purchased a new position in shares of Obseva during the 3rd quarter worth $720,000. 68.34% of the stock is currently owned by institutional investors.
Obseva (NASDAQ:OBSV) last released its quarterly earnings results on Thursday, November 8th. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.04. As a group, equities research analysts forecast that Obseva will post -1.86 earnings per share for the current fiscal year.
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Featured Story: What are the Benefits of Index Funds?
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.